Investors of Sarepta Therapeutics Have Deadlines to Take Action in Class Action Lawsuit

Recent Developments in Sarepta Therapeutics' Investor Class Action Lawsuit

Introduction
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) investors have recently been alerted to a significant opportunity to lead a class action lawsuit regarding alleged violations of the Securities Exchange Act of 1934. This news, announced by Robbins Geller Rudman & Dowd LLP, encourages those who purchased or acquired Sarepta securities from June 22, 2023, to June 24, 2025, to step forward and seek appointment as lead plaintiff in the case titled Dolgicer v. Sarepta Therapeutics, Inc. filed in the Southern District of New York.

Company Profile and Class Period
Sarepta Therapeutics is a biopharmaceutical firm that specializes in developing innovative therapies, particularly for Duchenne muscular dystrophy (Duchenne). During the class period, the company was primarily focused on its gene therapy product, ELEVIDYS, which was intended for a specific group of Duchenne patients. However, as detailed in the impending lawsuit, the company stands accused of maintaining misleading statements and failing to disclose crucial information about the safety risks associated with ELEVIDYS.

Allegations of Misconduct
According to the lawsuit, Sarepta executives are charged with several violations, including failing to inform investors that:
ELEVIDYS presented significant safety hazards to patients.
Protocols surrounding ELEVIDYS clinical trials did not sufficiently identify severe side effects.
* Intense adverse reactions to ELEVIDYS could lead to regulatory scrutiny and halt the therapy's recruitment processes.

The lawsuit particularly highlights critical incidents that impacted stock prices significantly. On March 18, 2025, news broke that a patient treated with ELEVIDYS experienced acute liver failure that resulted in death. Following this revelation, the stock price plummeted over 27%. The situation worsened on April 4, 2025, when regulatory authorities in the European Union requested a data monitoring committee review following the aforementioned death, causing the stock price to drop another 7%.

Subsequent disclosures revealed a second patient succumbed to acute liver failure on June 15, 2025, which led to Sarepta halting ELEVIDYS shipments for non-ambulatory patients and pausing related clinical studies. This triggered a staggering 42% decline in the stock price. Finally, on June 24, 2025, the FDA announced its investigation into the emerging reports of acute liver failure deaths connected to ELEVIDYS. The stock price fell by 8% in response to this news.

Opportunity for Investors
Robbins Geller announces that investors who experienced substantial financial losses during this class period may seek to be appointed as lead plaintiffs in this case. Serving as a lead plaintiff allows individuals to represent their interests and those of other investors in the ongoing litigation. According to the Private Securities Litigation Reform Act of 1995, anyone who purchased Sarepta securities during the defined period can apply for this role.

Seeking Legal Representation
Investors wishing to pursue this opportunity are encouraged to gather relevant information to present to Robbins Geller Rudman & Dowd LLP. The firm, recognized for its expertise in securities fraud and shareholder litigation, has achieved notable success in recovering monetary relief for investors. With a track record of securing billions for class action participants, Robbins Geller stands as a formidable representative for potential lead plaintiffs in this case.

Conclusion
As the August 25, 2025 deadline approaches for interested investors, it is crucial for affected parties to act promptly. Those facing substantial losses should consider their options carefully and may report their interest to the firm. For further information and to participate in this class action, investors can find details on contacting Robbins Geller on their official website. By stepping forward, investors can not only advocate for themselves but also contribute to a larger movement towards corporate accountability and transparency.